IARC（International Agency for Research on Cancer ），国际癌症研究机构，从1971年起组织专家组收集和评价世界各国有关化学物质对人类致癌危险性的资料，编辑出版《IARC关于化学物质致人类癌症危险性评价专题论文集》，并于1979年、 1982年和1987年三次组织专家组对上述专题论文集所评价的环境因子和类别、混合物及暴露环境对人类的致癌性进行再评价，并出版报告。自1987年专题论文集改名为《IARC关于致人类癌症危险性评价专题论文集》，并扩展到物理因子、生物因子致人类癌症危险性评价。 IARC关于化学物质致人类癌症危险性分类只与一种化学物致癌性证据的充分性(证据权重)有关，而并不涉及其致癌活性大小及其机制。IARC将化学物对人类致癌性资料(流行病学调查和病例报告)和对实验动物致癌性资料分为四级：致癌性证据充分、致癌性证据有限、致癌性证据不足及证据提示缺乏致癌性。对人致癌性证据充分是指在致癌物和人癌症发生之间有因果关系。致癌性证据有限是指因果关系的解释是可信的，但其他的解释如偶然性、偏倚、不能完全排除。致癌性证据不足是指资料的性质、一致性或统计学把握度不足以判断因果关系或没有对人致癌性的资料。证据提示缺乏致癌性是指有几个在已知人类充分暴露水平范围内的研究表明暴露水平与所研究的癌症无关联。
　　分类为人致癌物(组1)必须要有流行病学证据的支持。流行病学研究(队列研究和病例对照研究)试图为化学品接触与人群癌症发生(或死亡)增加的因果关系提供证据。癌症流行病学研究是比较困难的，一般是在人群接触某种化学品多年之后进行，可能有很多混杂因素，并往往受到经费和时间的限制。为治疗目的给以化学品(药品)和职业性接触，较易控制接触条件，但个体数和接触期限也往往受到限制。因此，对于很多化学品需要由动物致癌试验、短期试验等为接触此化学品的致癌危险性提供论据(主要用于)。
致癌性评价标准
　　实验动物致癌性资料证据评价标准：
　　(1) 致癌性证据充分指确立了受试物与肿瘤发生率(恶性或恶性和良性肿瘤合计)增加的因果关系：①见于两种或两种以上动物；②一个物种但经两次或多次独立的试验(包括不同时间或不同实验室或在不同实验方案条件下)；③在一个物种一次试验中，恶性肿瘤发生率、部位、肿瘤类型或发癌时间得到肯定的阳性结果。
　　(2) 致癌性证据有限指资料提示有致癌作用，但在作决定性评价中证据有限：①致癌性证据限于一个试验；②在设计、实施或结果解释的合理性方面尚有疑问；③仅有良性肿瘤、未确定致癌性潜力的损伤、或该种系中此肿瘤的自发率较高。
　　(3) 致癌性证据不足指资料由于重要的定性或定量上的限制，不足以证明致癌作用的存在与否，或没有实验动物致癌性的资料。
　　(4) 证据提示无致癌性是指有足够的资料(至少两种种系)证明该物质无致癌性。但需指出，证据提示无致癌性的结论必然限于所研究的种系、肿瘤部位和暴量水平。
致癌物分类
　　IARC根据对人类和对实验动物致癌性资料，以及在实验系统和人类其他有关的资料(包括癌前病变、肿瘤病理学、遗传毒性、，代谢和动力学，理化参数及同类的生物因子)进行综合评价，将环境因子和类别、混合物及暴露环境与人类癌症的关系分为下列五类四组：第一类：致癌　　组1，对人类是致癌物。对人类致癌性证据充分者属于本组。如吸烟和二手烟。第二类：很可能致癌　　组2，对人类是很可能或可能致癌物。又分为两组，即组2A和组2B。
　　组2A，对人类很可能(probably)是致癌物，指对人类致癌性证据有限。对实验动物致癌性证据充分。如生产艺术玻璃、常用电吹风的理发师。第三类：可能致癌　　组2B，对人类是可能(possible)致癌物，指对人类致癌性证据有限，对实验动物致癌性证据并不充分；或指对人类致癌性证据不足，对实验动物致癌性证据充分。第四类：未知　　组3，现有的证据不能对人类致癌性进行分类。第五类：很可能不致癌　　组4，对人类可能是非致癌物。
致癌物五类明细表
　　IARC专家组在2010年1月最新报告对834种环境因子和类别、混合物及暴露环境与人类癌症关系评价结果，
　　其中组1有100种，组1B有68种，组2B有246种，组3有516种，组4有1种。
　　IARC对化学物质引起人类癌症危险性评价，是目前公认的权威性资料。在要了解某种化学物的致癌性时，应首先查阅IARC的资料(网址http：193．51．164．11/monoeval/crthgr01．html)。
　　毒理学网 日
　　Overall Evaluations of ity to Humans
　　Group 1: Carcinogenic to humans (100)
　　Agents and groups of agents
　　4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7; 1987)
　　Arsenic [] and arsenic compounds (Vol. 23, Suppl. 7; 1987) (NB:
　　This evaluation applies to the group of compounds as a whole and not
　　necessarily to all individual compounds within the group)
　　 [] (Vol. 14, Suppl. 7; 1987)
　　Azathioprine [446-86-6] (Vol. 26, Suppl. 7; 1987)
　　Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987)
　　Benzidine [92-87-5] (Vol. 29, Suppl. 7; 1987)
　　Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　(NB: Overall evaluation upgraded from 2B to 1 based on mechanistic and
　　other relevant data)
　　 [] and beryllium compounds (Vol. 58; 1993)
　　N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol.
　　4, Suppl. 7; 1987)
　　Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl ether [107-30-2]
　　(technical-grade)
　　(Vol. 4, Suppl. 7; 1987)
　　1,4-Butanediol dimethanesulfonate (B Myleran) [55-98-1] (Vol. 4,
　　Suppl. 7; 1987)
　　Cadmium [] and cadmium compounds (Vol. 58; 1993)
　　Chlorambucil [305-03-3] (Vol. 26, Suppl. 7; 1987)
　　1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU;
　　Semustine) [] (Suppl. 7; 1987)
　　Chromium[VI] (Vol. 49; 1990)
　　Ciclosporin [] (Vol. 50; 1990)
　　Cyclophosphamide [50-18-0] [] (Vol. 26, Suppl. 7; 1987)
　　Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7; 1987)
　　Epstein-Barr virus (Vol. 70; 1997)
　　Erionite [] (Vol. 42, Suppl. 7; 1987)
　　Estrogen- menopausal therapy (combined) (Vol. 72, Vol. 91; in
　　preparation)
　　Estrogen-progestogen oral contraceptives (combined) (Vol. 72, Vol. 91; in
　　preparation)
　　(NB: There is also
evidence in humans that these agents
　　a protective effect against cancer in the
　　Estrogens, nonsteroidal (Suppl. 7; 1987) (NB: This evaluation applies to
　　the group of compounds as a whole and not necessarily to all individual
　　compounds within the group)
　　Estrogens, steroidal (Suppl. 7; 1987) (NB: This evaluation applies to
　　the group of compounds as a whole and not necessarily to all individual
　　compounds within the group)
　　Estrogen therapy, postmenopausal (Vol. 72; 1999)
　　Ethylene oxide [75-21-8] (Vol. 60; 1994) (NB: Overall evaluation upgraded
　　from 2A to 1 with supporting evidence from other relevant data)
　　 [] in combination with cisplatin and
　　76; 2000)
　　Formaldehyde [50-00-0] (Vol. 88; 2006)
　　Gallium arsenide [] (Vol. 86; 2006)
　　[Gamma Radiation: see X- and Gamma (g)-Radiation]
　　Helicobacter pylori (infection with) (Vol. 61; 1994)
　　Hepatitis B virus (chronic infection with) (Vol. 59; 1994)
　　Hepatitis C virus (chronic infection with) (Vol. 59; 1994)
　　Human immunodeficiency virus type 1 (infection with) (Vol. 67; 1996)
　　Human papillomavirus types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
　　and 66 (Vol. 64, Vol. 90; in preparation) (NB: The HPV types that have
　　been classified as carcinogenic to humans can differ by an order of
　　magnitude in risk for cervical cancer)
　　Human T-cell lymphotropic virus type I (Vol. 67; 1996)
　　Melphalan [148-82-3] (Vol. 9, Suppl. 7; 1987)
　　8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation
　　(Vol. 24, Suppl. 7; 1987)
　　MOPP and other combined chemotherapy including alkylating agents (Suppl.
　　7; 1987)
　　Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987)
　　2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7; 1987)
　　Neutrons (Vol. 75; 2000) (NB: Overall evaluation upgraded from 2B to 1
　　with supporting evidence from other relevant data)
　　Nickel compounds (Vol. 49; 1990)
　　N‘-Nitrosonornicotine (NNN) [] and
　　4-(N-Nitrosomethylamino)-1-(3-pyridyl)- 1-butanone (NNK) []
　　(Vol. 37, Suppl. 7, Vol. 89; in preparation) (NB: Overall evaluation
　　upgraded from 2B to 1 based on mechanistic and other relevant data)
　　[: see Estrogen]
　　Opisthorchis viverrini (infection with) (Vol. 61; 1994)
　　[Oral contraceptives, combined estrogen-progestogen: see
　　Estrogen-progestogen oral contraceptives (combined)]
　　Oral contraceptives, sequential (Suppl. 7; 1987)
　　Phosphorus-32, as phosphate (Vol. 78; 2001)
　　-239 and its decay products (may contain plutonium-240 and other
　　isotopes), as aerosols (Vol. 78; 2001)
　　Radioiodines, short-lived isotopes, including iodine-131, from atomic
　　reactor accidents and nuclear weapons detonation (exposure during
　　childhood) (Vol. 78; 2001)
　　Radionuclides, a-particle-emitting, internally deposited (Vol. 78; 2001)
　　(NB: Specific radionuclides for which there is sufficient evidence for
　　carcinogenicity to humans are also listed
as Group 1 agents)
　　Radionuclides, b-particle-emitting, internally deposited (Vol. 78; 2001)
　　(NB: Specific radionuclides for which there is sufficient evidence for
　　carcinogenicity to humans are also listed individually as Group 1 agents)
　　-224 and its decay products (Vol. 78; 2001)
　　Radium-226 and its decay products (Vol. 78; 2001)
　　Radium-228 and its decay products (Vol. 78; 2001)
　　Radon-222 [] and its decay products (Vol. 43, Vol. 78; 2001)
　　Schistosoma haematobium (infection with) (Vol. 61; 1994)
　　Silica [], crystalline (inhaled in the form of quartz or
　　cristobalite from occupational sources) (Vol. 68; 1997)
　　Solar radiation (Vol. 55; 1992)
　　 containing asbestiform fibres (Vol. 42, Suppl. 7; 1987)
　　Tamoxifen [] (Vol. 66; 1996) (NB: There is also
　　evidence that tamoxifen reduces the risk of contralateral breast cancer)
　　2,3,7,8-Tetrachlorodibenzo-para-dioxin [] (Vol. 69; 1997) (NB:
　　Overall evaluation upgraded from 2A to 1 with supporting evidence from
　　other relevant data)
　　Thiotepa [52-24-4] (Vol. 50; 1990)
　　-232 and its decay products, administered intravenously as a
　　colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001)
　　Treosulfan [299-75-2] (Vol. 26, Suppl. 7; 1987)
　　Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7; 1987)
　　X- and Gamma (g)-Radiation (Vol. 75; 2000)
　　Mixtures
　　Aflatoxins (naturally occurring mixtures of) [] (Vol. 56, Vol.
　　82; 2002)
　　Alcoholic beverages (Vol. 44; 1988)
　　 nut (Vol. 85; 2004) (NB: Overall evaluation based on human data,
　　animal data, and mechanistic and other relevant data)
　　 quid with tobacco (Vol. 85; 2004)
　　Betel quid without tobacco (Vol. 85; 2004)
　　Coal-tar pitches [] (Vol. 35, Suppl. 7; 1987)
　　Coal- [] (Vol. 35, Suppl. 7; 1987)
　　Herbal remedies containing plant species of the genus Aristolochia (Vol.
　　82; 2002)
　　Household combustion of coal, indoor emissions from (Vol. 95; in
　　preparation)
　　Mineral oils,
treated (Vol. 33, Suppl. 7; 1987)
　　Phenacetin,
mixtures containing (Suppl. 7; 1987)
　　Salted fish (Chinese-style) (Vol. 56; 1993)
　　Shale-oils [] (Vol. 35, Suppl. 7; 1987)
　　Soots (Vol. 35, Suppl. 7; 1987)
　　Tobacco烟草,
(Vol. 37, Suppl. 7, Vol. 89; in preparation)
　　Wood dust (Vol. 62; 1995)
　　Exposure circumstances
　　Aluminium production (Vol. 34, Suppl. 7; 1987)
　　Arsenic in drinking-water (Vol. 84; 2004)
　　Auramine, manufacture of (Suppl. 7; 1987)
　　Boot and shoe manufacture and repair (Vol. 25, Suppl. 7; 1987)
　　 sweeping (Vol. 92; in preparation)
　　Coal gasification (Vol. 34, Suppl. 7, Vol. 92; in preparation)
　　Coal-tar distillation (Vol. 92; in preparation)
　　Coke production (Vol. 34, Suppl. 7, Vol. 92; in preparation)
　　Furniture and cabinet making (Vol. 25, Suppl. 7; 1987)
　　Haematite mining (underground) with exposure to radon (Vol. 1, Suppl. 7;
　　 smoking (exposure to
or ‘environmental‘ tobacco
　　smoke) (Vol. 83; 2004)
　　Iron and steel founding (Vol. 34, Suppl. 7; 1987)
　　Isopropyl alcohol manufacture (strong-acid process) (Suppl. 7; 1987)
　　Magenta, manufacture of (Vol. 57; 1993)
　　Painter (occupational exposure as a) (Vol. 47; 1989)
with coal-tar pitch (Vol. 92; in preparation)
　　Rubber industry (Vol. 28, Suppl. 7; 1987)
　　Strong-inorganic-acid mists containing sulfuric acid (occupational
　　exposure to) (Vol. 54; 1992)
　　Tobacco smoking 吸烟and tobacco smoke 二手烟(Vol. 83; 2004)
　　Last updated: 13 December 2006
　　Group 2A: Probably carcinogenic to humans(68)
　　Agents and groups of agents
　　Acrylamide [79-06-1] (Vol. 60; 1994) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Adriamycin [] (Vol. 10, Suppl. 7; 1987) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　Androgenic (anabolic) steroids (Suppl. 7; 1987)
　　Aristolochic acids (naturally occurring mixtures of) (Vol. 82; 2002)
　　Azacitidine [320-67-2] (Vol. 50; 1990) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Benzidine-based dyes (Suppl. 7; 1987) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26, Suppl.7; 1987)
　　1,3-Butadiene [106-99-0] (Vol. 71; 1999)
　　Captafol [] (Vol. 53; 1991) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Chloramphenicol [56-75-7] (Vol. 50; 1990) (NB: Overall evaluation
　　upgraded from 2B to 2A with supporting evidence from other relevant data)
　　a-Chlorinated toluenes (benzal chloride [98-87-3], benzotrichloride
　　[98-07-7], benzyl chloride [100-44-7]) and benzoyl chloride [98-88-4]
　　(combined exposures) (Vol. 29, Suppl. 7, Vol. 71; 1999)
　　1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [](Vol. 26,
　　Suppl. 7; 1987)
　　(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence
　　from other relevant data)
　　4-Chloro-ortho-toluidine [95-69-2] (Vol. 77; 2000)
　　Chlorozotocin [] (Vol. 50; 1990) (NB: Overall evaluation
　　upgraded from 2B to 2A with supporting evidence from other relevant data)
　　Cisplatin [] (Vol. 26, Suppl. 7; 1987) (NB: Overall evaluation
　　upgraded from 2B to 2A with supporting evidence from other relevant data)
　　Clonorchis sinensis (infection with) (Vol. 61; 1994) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　Cyclopenta[cd]pyrene [] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation) (NB: Overall evaluation upgraded from 2B to 2A with
　　supporting evidence from other relevant data)
　　Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation) (NB: Overall evaluation upgraded from 2B to 2A with
　　supporting evidence from other relevant data)
　　Dibenzo[a,l]pyrene [191-30-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence
　　from other relevant data)
　　Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl. 7, Vol. 71; 1999)
　　(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence
　　from other relevant data)
　　1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol. 71; 1999) (NB:
　　Overall evaluation upgraded from 2B to 2A with supporting evidence from
　　other relevant data)
　　Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71; 1999) (NB:
　　Overall evaluation upgraded from 2B to 2A with supporting evidence from
　　other relevant data)
　　Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71; 1999) (NB:
　　Overall evaluation upgraded from 2B to 2A with supporting evidence from
　　other relevant data)
　　Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol. 71; 1999) (NB:
　　Overall evaluation upgraded from 2B to 2A with supporting evidence from
　　other relevant data)
　　N-Ethyl-N-nitrosourea [759-73-9] (Vol. 17, Suppl.7; 1987) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　Etoposide [] (Vol. 76; 2000) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Glycidol [556-52-5] (Vol. 77; 2000) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Indium phosphide [] (Vol. 86; 2006) (NB: Overall evaluation
　　upgraded from 2B to 2A)
　　IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [] (Vol. 56; 1993)
　　(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence
　　from other relevant data)
　　Kaposi‘s
herpesvirus/human herpesvirus 8 (Vol. 70; 1997)
　　Lead compounds, inorganic (Vol. 87; 2006)
　　5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　4,4′-Methylene bis(2-chloroaniline) (MOCA) [101-14-4] (Vol.57; 1993)
　　(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence
　　from other relevant data)
　　Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7, Vol. 71; 1999)
　　(NB: Overall evaluation upgraded from 2B to 2A with supporting evidence
　　from other relevant data)
　　N-Methyl-N′-nitro-N-nitrosoguanidine(MNNG) [70-25-7] (Vol. 4, Suppl. 7;
　　1987) (NB: Overall evaluation upgraded from 2B to 2A with supporting
　　evidence from other relevant data)
　　N-Methyl-N-nitrosourea [684-93-5] (Vol. 17, Suppl.7; 1987) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　Nitrate or nitrite (ingested) under conditions that result in endogenous
　　nitrosation (Vol. 94; in preparation)
　　Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987)
　　N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl. 7; 1987) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl. 7; 1987) (NB: Overall
　　evaluation upgraded from 2B to 2A with supporting evidence from other
　　relevant data)
　　Phenacetin [62-44-2] (Vol. 24, Suppl. 7; 1987)
　　Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl. 7; 1987) (NB:
　　Overall evaluation upgraded from 2B to 2A with supporting evidence from
　　other relevant data)
　　Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994) (NB: Overall evaluation
　　upgraded from 2B to 2A with supporting evidence from other relevant data)
　　Teniposide [] (Vol. 76; 2000) (NB: Overall evaluation
　　upgraded from 2B to 2A with supporting evidence from other relevant data)
　　Tetrachloroethylene [127-18-4] (Vol. 63; 1995)
　　ortho-Toluidine [95-53-4] (Vol. 77; 2000)
　　Trichloroethylene [79-01-6] (Vol. 63; 1995)
　　1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995)
　　Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20, Suppl. 7, Vol.
　　71;1999) (NB: Overall evaluation upgraded from 2B to 2A with supporting
　　evidence from other relevant data)
　　Ultraviolet radiation A (Vol. 55; 1992) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Ultraviolet radiation B (Vol. 55; 1992) (NB: Overall evaluation upgraded
　　from 2B to 2A with supporting evidence from other relevant data)
　　Ultraviolet radiation C (Vol. 55; 1992) (NB: Overall evaluation
　　upgraded from 2B to 2A with supporting evidence from other relevant data)
　　Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71; 1999) (NB:
　　Overall evaluation upgraded from 2B to 2A with supporting evidence from
　　other relevant data)
　　Vinyl fluoride [75-02-5] (Vol. 63; 1995)
　　Mixtures
　　Creosotes [] (Vol. 35, Suppl. 7, Vol. 92; in preparation)
　　Diesel engine exhaust (Vol. 46; 1989)
　　High-temperature frying, emissions from (Vol. 95; in preparation)
　　Hot mate (Vol. 51; 1991)
　　Household combustion of biomass fuel (primarily wood), indoor emissions
　　from (Vol. 95; in preparation)
　　Non- insecticides (occupational exposures in spraying and
　　application of) (Vol. 53; 1991)
　　Polychlorinated biphenyls [] (Vol. 18, Suppl. 7; 1987)
　　Exposure circumstances
　　Art glass, glass
and pressed ware (manufacture of) (Vol. 58;
　　Carbon electrode manufacture (Vol. 92; in preparation)
　　Cobalt metal with tungsten carbide (Vol. 86; 2006)
　　 or barber (occupational exposure as a) (Vol. 57; 1993)
　　Petroleum refining (occupational exposures in) (Vol. 45; 1989)
　　Sunlamps and sunbeds (use of) (Vol. 55; 1992)
　　Last updated: 29 November 2006
　　Group 2B: Possibly carcinogenic to humans (246)
　　Agents and groups of agents
　　A-a-C (2-Amino-9H-pyrido[2,3-b]indole) [] (Vol. 40, Suppl. 7;
　　 [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)
　　Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999)
　　Acrylonitrile [107-13-1] (Vol. 71; 1999)
　　AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [] (Vol.31,
　　Suppl. 7; 1987)
　　Aflatoxin M1 [] (Vol. 56; 1993)
　　para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7; 1987)
　　ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl. 7; 1987)
　　2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5] (Vol. 7, Suppl.
　　7; 1987)
　　Amsacrine [] (Vol. 76; 2000)
　　ortho-Anisidine [90-04-0] (Vol. 73; 1999)
　　Antimony trioxide [] (Vol. 47; 1989)
　　Aramite? [140-57-8] (Vol. 5, Suppl. 7; 1987)
　　Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7; 1987)
　　Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987)
　　Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999) (NB: Overall
　　evaluation upgraded from 3 to 2B with supporting evidence from other
　　relevant data)
　　Benz[j]aceanthrylene [202-33-5] (Vol. 92; in preparation) (NB: Overall
　　evaluation upgraded from 3 to 2B with supporting mechanistic and other
　　relevant data)
　　Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　Benzo[b]fluoranthene [205-99-2] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation)
　　Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation)
　　Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation)
　　Benzofuran [271-89-6] (Vol. 63; 1995)
　　Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation) (NB: Overall evaluation upgraded from 3 to 2B with
　　supporting evidence from other relevant data)
　　Benzyl violet 4B [] (Vol. 16, Suppl. 7; 1987)
　　2,2-Bis(bromomethyl)propane-1,3-diol [] (Vol. 77; 2000)
　　Bleomycins [] (Vol. 26, Suppl. 7; 1987) (NB: Overall
　　evaluation upgraded from 3 to 2B with supporting evidence from other
　　relevant data)
　　 fern (Vol. 40, Suppl. 7; 1987)
　　Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999)
　　Butylated hydroxyanisole (BHA) [] (Vol. 40, Suppl. 7;1987)
　　b-Butyrolactone [] (Vol. 11, Suppl. 7, Vol. 71; 1999)
　　Caffeic acid [331-39-5] (Vol. 56; 1993)
　　Carbon black [] (Vol. 65, Vol. 93; in preparation)
　　Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol. 71; 1999)
　　Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)
　　Chlordane [57-74-9] (Vol. 79; 2001)
　　Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987)
　　Chlorendic acid [115-28-6] (Vol. 48; 1990)
　　para-Chloroaniline [106-47-8] (Vol. 57; 1993)
　　3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone [] (Vol.
　　84; 2004)
　　 [67-66-3] (Vol. 73; 1999)
　　1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995)
　　Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987)
　　4-Chloro-ortho-phenylenediamine [95-83-0] (Vol. 27, Suppl.7; 1987)
　　Chloroprene [126-99-8] (Vol. 71; 1999)
　　Chlorothalonil [] (Vol. 73; 1999)
　　Chrysene [218-01-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　CI Acid Red 114 [] (Vol. 57; 1993)
　　CI Basic Red 9 [569-61-9] (Vol. 57; 1993)
　　CI Direct Blue 15 [] (Vol. 57; 1993)
　　Citrus Red No. 2 [] (Vol. 8, Suppl. 7; 1987)
　　Cobalt [] and cobalt compounds (Vol. 52; 1991) (NB: Evaluated
　　as a group)
　　Cobalt sulfate [] and other soluble cobalt(II) salts (Vol. 86;
　　para-Cresidine [120-71-8] (Vol. 27, Suppl. 7; 1987)
　　Cycasin [] (Vol. 10, Suppl. 7; 1987)
　　Dacarbazine [] (Vol. 26, Suppl. 7; 1987)
　　Dantron (C 1,8-Dihydroxyanthraquinone) [117-10-2] (Vol. 50; 1990)
　　Daunomycin [] (Vol. 10, Suppl. 7; 1987)
　　DDT [p,p‘-DDT, 50-29-3] (Vol. 53; 1991)
　　N,N‘-Diacetylbenzidine [613-35-4] (Vol. 16, Suppl.7; 1987)
　　2,4-Diaminoanisole [615-05-4] (Vol. 79; 2001)
　　4,4‘-Diaminodiphenyl ether [101-80-4] (Vol. 29, Suppl. 7; 1987)
　　2,4-Diaminotoluene [95-80-7] (Vol. 16, Suppl. 7; 1987)
　　Dibenz[a,h] [226-36-8] (Vol. 32, Suppl. 7; 1987)
　　Dibenz[a,j]acridine [224-42-0] (Vol. 32, Suppl. 7; 1987)
　　7H-Dibenzo[c,g]carbazole [194-59-2] (Vol. 32, Suppl.7; 1987)
　　Dibenzo[a,h]pyrene [189-64-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　Dibenzo[a,i]pyrene [189-55-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　1,2-Dibromo-3-chloropropane [96-12-8] (Vol. 20, Suppl. 7, Vol. 71; 1999)
　　2,3-Dibromopropan-1-ol [96-13-9] (Vol. 77; 2000)
　　Dichloroacetic acid [79-43-6] (Vol. 84; 2004)
　　para-Dichlorobenzene [106-46-7] (Vol. 73; 1999)
　　3,3‘-Dichlorobenzidine [91-94-1] (Vol. 29, Suppl. 7; 1987)
　　3,3‘-Dichloro-4,4‘-diaminodiphenyl ether [] (Vol. 16,Suppl. 7;
　　1,2-Dichloroethane [107-06-2] (Vol. 20, Suppl. 7, Vol. 71; 1999)
　　Dichloromethane (methylene chloride) [75-09-2] (Vol. 71; 1999)
　　1,3-Dichloropropene [542-75-6] (technical-grade) (Vol. 41, Suppl.7, Vol.
　　71; 1999)
　　Dichlorvos [62-73-7] (Vol. 53; 1991)
　　1,2-Diethylhydrazine [] (Vol. 4, Suppl. 7, Vol. 71; 1999)
　　Diglycidyl resorcinol ether [101-90-6] (Vol. 36, Suppl. 7, Vol. 71; 1999)
　　Dihydrosafrole [94-58-6] (Vol. 10, Suppl. 7; 1987)
　　Diisopropyl sulfate [] (Vol. 54, Vol. 71; 1999)
　　3,3‘-Dimethoxybenzidine (ortho-Dianisidine) [119-90-4] (Vol. 4, Suppl. 7;
　　para-Dimethylaminoazobenzene [60-11-7] (Vol. 8, Suppl. 7; 1987)
　　trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole
　　[] (Vol. 7, Suppl. 7; 1987)
　　2,6-Dimethylaniline (2,6-Xylidine) [87-62-7] (Vol. 57; 1993)
　　3,3‘-Dimethylbenzidine (ortho-Tolidine) [119-93-7] (Vol.1, Suppl. 7; 1987)
　　1,1-Dimethylhydrazine [57-14-7] (Vol. 4, Suppl. 7, Vol. 71; 1999)
　　3,7-Dinitrofluoranthene [-5] (Vol. 65; 1996)
　　3,9-Dinitrofluoranthene [] (Vol. 65; 1996)
　　1,6-Dinitropyrene [] (Vol. 46; 1989)
　　1,8-Dinitropyrene [] (Vol. 46; 1989)
　　2,4-Dinitrotoluene [121-14-2] (Vol. 65; 1996)
　　2,6-Dinitrotoluene [606-20-2] (Vol. 65; 1996)
　　1,4-Dioxane [123-91-1] (Vol. 11, Suppl. 7, Vol. 71; 1999)
　　Disperse Blue 1 [] (Vol. 48; 1990)
　　1,2-Epoxybutane [106-88-7] (Vol. 47, Vol. 71; 1999) (NB: Overall
　　evaluation upgraded from 3 to 2B with supporting evidence from other
　　relevant data)
　　Ethyl acrylate [140-88-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)
　　Ethylbenzene [100-41-4] (Vol. 77; 2000)
　　Ethyl methanesulfonate [62-50-0] (Vol. 7, Suppl. 7; 1987)
　　[Foreign bodies: see Surgical implants and other foreign bodies]
　　2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole [] (Vol. 7,
　　Suppl. 7; 1987)
　　Fumonisin B1 [-0] (Vol. 82; 2002)
　　Furan [110-00-9] (Vol. 63; 1995)
　　Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3‘,2‘-d]imidazole) []
　　(Vol. 40, Suppl. 7; 1987)
　　Glu-P-2 (2-Aminodipyrido[1,2-a:3‘,2‘-d]imidazole)[] (Vol. 40,
　　Suppl. 7; 1987)
　　Glycidaldehyde [765-34-4] (Vol. 11, Suppl. 7, Vol. 71; 1999)
　　Griseofulvin [126-07-8] (Vol. 79; 2001)
　　HC Blue No. 1 [] (Vol. 57; 1993)
　　Heptachlor [76-44-8] (Vol. 79; 2001)
　　Hexachlorobenzene [118-74-1] (Vol. 79; 2001)
　　Hexachloroethane [67-72-1] (Vol. 73; 1999)
　　Hexachlorocyclohexanes (Vol. 20, Suppl. 7; 1987)
　　Hexamethylphosphoramide [680-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)
　　Human immunodeficiency virus type 2 (infection with) (Vol. 67; 1996)
　　Human papillomavirus types 6 and 11 (Vol. 90; in preparation)
　　Human papillomavirus genus beta (some types) (Vol. 90; in preparation)
　　Hydrazine [302-01-2] (Vol. 4, Suppl. 7, Vol. 71; 1999)
　　1-Hydroxyanthraquinone [129-43-1] (Vol. 82; 2002)
　　Indeno[1,2,3-cd]pyrene [193-39-5] (Vol. 32, Suppl. 7, Vol. 92; in
　　preparation)
　　Iron-dextran complex [] (Vol. 2, Suppl. 7; 1987)
　　Isoprene [78-79-5] (Vol. 60, Vol. 71; 1999)
　　Lasiocarpine [303-34-4] (Vol. 10, Suppl. 7; 1987)
　　Lead [] (Vol. 23, Suppl. 7; 1987)
　　Magenta [632-99-5] (containing CI Basic Red 9) (Vol. 57; 1993)
　　Magnetic fields (extremely low-frequency) (Vol. 80; 2002)
　　MeA-a-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole) [] (Vol. 40,
　　Suppl. 7; 1987)
　　Medroxyprogesterone acetate [71-58-9] (Vol. 21, Suppl. 7; 1987)
　　MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) [] (Vol. 56;
　　MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline) [] (Vol.
　　56; 1993)
　　Merphalan [531-76-0] (Vol. 9, Suppl. 7; 1987)
　　2-Methylaziridine (Propyleneimine) [75-55-8] (Vol. 9, Suppl. 7, Vol. 71;
　　Methylazoxymethanol acetate [592-62-1] (Vol. 10, Suppl. 7; 1987)
　　5-Methylchrysene [] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
　　4,4‘-Methylene bis(2-methylaniline) [838-88-0] (Vol. 4, Suppl.7; 1987)
　　4,4‘-Methylenedianiline [101-77-9] (Vol. 39, Suppl. 7; 1987)
　　Methylmercury compounds (Vol. 58; 1993) (NB: Evaluated as a group)
　　2-Methyl-1-nitroanthraquinone [129-15-7] (uncertain purity) (Vol.27,
　　Suppl. 7; 1987)
　　N-Methyl-N-nitrosourethane [615-53-2] (Vol. 4, Suppl.7; 1987)
　　Methylthiouracil [56-04-2] (Vol. 79; 2001)
　　Metronidazole [443-48-1] (Vol. 13, Suppl. 7; 1987)
　　Microcystin-LR [-2] (Vol. 94; in preparation) (NB: Overall
　　evaluation upgraded from 3 to 2B based on mechanistic and other relevant
　　Mirex [] (Vol. 20, Suppl. 7; 1987)
　　Mitomycin C [50-07-7] (Vol. 10, Suppl. 7; 1987)
　　Mitoxantrone [] (Vol. 76; 2000)
　　Monocrotaline [315-22-0] (Vol. 10, Suppl. 7; 1987)
　　5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone
　　[] (Vol. 7, Suppl. 7; 1987)
　　Nafenopin [] (Vol. 24, Suppl. 7; 1987)
　　Naphthalene [91-20-3] (Vol. 82; 2002)
　　Nickel, metallic [] and alloys (Vol. 49; 1990)
　　Niridazole [61-57-4] (Vol. 13, Suppl. 7; 1987)
　　Nitrilotriacetic acid [139-13-9] and its salts (Vol. 73; 1999) (NB:
　　Evaluated as a group)
　　5-Nitroacenaphthene [602-87-9] (Vol. 16, Suppl. 7; 1987)
　　2-Nitroanisole [91-23-6] (Vol. 65; 1996)
　　Nitrobenzene [98-95-3] (Vol. 65; 1996)
　　6-Nitrochrysene [] (Vol. 46; 1989)
　　Nitrofen [] (technical-grade) (Vol. 30, Suppl. 7; 1987)
　　2-Nitrofluorene [607-57-8] (Vol. 46; 1989)
　　1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone [555-84-0] (Vol.7,
　　Suppl. 7; 1987)
　　N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide [531-82-8] (Vol. 7, Suppl. 7;
　　Nitrogen mustard N-oxide [126-85-2] (Vol. 9, Suppl. 7;1987)
　　Nitromethane [75-52-5] (Vol. 77; 2000)
　　2-Nitropropane [79-46-9] (Vol. 29, Suppl. 7, Vol. 71; 1999)
　　1-Nitropyrene [] (Vol. 46; 1989)
　　4-Nitropyrene [] (Vol. 46; 1989)
　　N-Nitrosodi-n-butylamine [924-16-3] (Vol. 17, Suppl.7; 1987)
　　N-Nitrosodiethanolamine [] (Vol. 17, Suppl. 7, Vol. 77; 2000)
　　N-Nitrosodi-n-propylamine [621-64-7] (Vol. 17, Suppl.7; 1987)
　　3-(N-Nitrosomethylamino)propionitrile [] (Vol. 85; 2004)
　　N-Nitrosomethylethylamine [] (Vol. 17, Suppl. 7; 1987)
　　N-Nitrosomethylvinylamine [] (Vol. 17, Suppl. 7; 1987)
　　N-Nitrosomorpholine [59-89-2] (Vol. 17, Suppl. 7; 1987)
　　N-Nitrosopiperidine [100-75-4] (Vol. 17, Suppl. 7; 1987)
　　N-Nitrosopyrrolidine [930-55-2] (Vol. 17, Suppl. 7; 1987)
　　N-Nitrososarcosine [] (Vol. 17, Suppl. 7; 1987)
　　Ochratoxin A [303-47-9] (Vol. 56; 1993)
　　Oil Orange SS [] (Vol. 8, Suppl. 7; 1987)
　　Oxazepam [604-75-1] (Vol. 66; 1996)
　　Palygorskite (attapulgite) [] (long fibres, & 5 micrometres)
　　(Vol. 68; 1997)
　　Panfuran S [794-93-4] (containing dihydroxymethylfuratrizine)
　　(Vol. 24, Suppl. 7; 1987)
　　Phenazopyridine hydrochloride [136-40-3] (Vol. 24, Suppl. 7; 1987)
　　Phenobarbital [50-06-6] (Vol. 79; 2001)
　　 [77-09-8] (Vol. 76; 2000)
　　Phenoxybenzamine hydrochloride [63-92-3] (Vol. 24, Suppl. 7; 1987)
　　Phenyl glycidyl ether [122-60-1] (Vol. 47, Vol. 71; 1999)
　　Phenytoin [57-41-0] (Vol. 66; 1996)
　　PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) [-5] (Vol.
　　56; 1993)
　　Polychlorophenols and their sodium salts (mixed exposures) (Vol. 41,
　　Suppl. 7, Vol. 53, Vol. 71; 1999)
　　Ponceau MX [] (Vol. 8, Suppl. 7; 1987)
　　Ponceau 3R [] (Vol. 8, Suppl. 7; 1987)
　　Potassium bromate [] (Vol. 73; 1999)
　　Progestins (Suppl. 7; 1987)
　　Progestogen-only contraceptives (Vol. 72; 1999)
　　1,3-Propane sultone [] (Vol. 4, Suppl. 7, Vol. 71; 1999)
　　b-Propiolactone [57-57-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)
　　Propylene oxide [75-56-9] (Vol. 60; 1994)
　　Propylthiouracil [51-52-5] (Vol. 79; 2001)
　　Refractory ceramic fibres (Vol. 43, Vol. 81; 2002)
　　Riddelliine [] (Vol. 10, Suppl. 7, Vol. 82; 2002)
　　Safrole [94-59-7] (Vol. 10, Suppl. 7; 1987)
　　Schistosoma japonicum (infection with) (Vol. 61; 1994)
　　Sodium ortho-phenylphenate [132-27-4] (Vol. 73; 1999)
　　Special-purpose fibres such as E-glass and ‘475‘ glass fibres (Vol. 81;
　　Sterigmatocystin [] (Vol. 10, Suppl. 7; 1987)
　　Streptozotocin [] (Vol. 17, Suppl. 7; 1987)
　　Styrene [100-42-5] (Vol. 60, 82; 2002)
　　Sulfallate [95-06-7] (Vol. 30, Suppl. 7; 1987)
　　Surgical implants and other foreign bodies (Vol. 74; 1999):
　　- Polymeric implants prepared as thin smooth film (with the exception of
　　poly(glycolic acid))
　　- Metallic implants prepared as thin smooth films
　　- Implanted foreign bodies of metallic cobalt, metallic nickel and an
　　alloy powder containing 66-67% nickel, 13-16% chromium and 7% iron
　　Tetrafluoroethylene [116-14-3] (Vol. 19, Suppl. 7, Vol. 71; 1999)
　　Tetranitromethane [509-14-8] (Vol. 65; 1996)
　　Thioacetamide [62-55-5] (Vol. 7, Suppl. 7; 1987)
　　4,4‘-Thiodianiline [139-65-1] (Vol. 27, Suppl. 7; 1987)
　　Titanium dioxide [] (Vol. 47, Vol. 93; in preparation)
　　Thiouracil [141-90-2] (Vol. 79; 2001)
　　Toluene diisocyanates [] (Vol. 39, Suppl. 7, Vol. 71; 1999)
　　Trichlormethine (Trimustine hydrochloride) [817-09-4] (Vol. 50; 1990)
　　Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole)[] (Vol.
　　31, Suppl. 7; 1987)
　　Trp-P-2 (3-Amino-1-methyl-5H-pyrido[4,3-b]indole)[] (Vol. 31,
　　Suppl. 7; 1987)
　　Trypan blue [72-57-1] (Vol. 8, Suppl. 7; 1987)
　　Uracil mustard [66-75-1] (Vol. 9, Suppl. 7; 1987)
　　Urethane [51-79-6] (Vol. 7, Suppl. 7; 1987)
　　Vanadium pentoxide [] (Vol. 86; in preparation)
　　Vinyl acetate [108-05-4] (Vol. 63; 1995)
　　4-Vinylcyclohexene [100-40-3] (Vol. 60; 1994)
　　4-Vinylcyclohexene diepoxide [106-87-6] (Vol. 60; 1994)
　　Zalcitabine [] (Vol. 76; 2000)
　　Zidovudine (AZT) [] (Vol. 76; 2000)
　　Mixtures
　　Bitumens [], extracts of steam-refined and air-refined (Vol. 35,
　　Suppl. 7; 1987)
　　Carrageenan [], degraded (Vol. 31, Suppl. 7; 1987)
　　Chlorinated paraffins of average carbon chain length C12 and average
　　degree of chlorination approximately 60% (Vol. 48; 1990)
　　Coffee (urinary ) (Vol. 51; 1991) (NB: There is some evidence of
　　an inverse relationship between coffee drinking and cancer of the large
　　; coffee drinking could not be classified as to its carcinogenicity
　　to other organs)
　　Diesel fuel, marine (Vol. 45; 1989) (NB: Overall evaluation upgraded
　　from 3 to 2B with supporting evidence from other relevant data)
　　Engine exhaust, gasoline (Vol. 46; 1989)
　　Fuel oils, residual (heavy) (Vol. 45; 1989)
　　Gasoline (Vol. 45; 1989) (NB: Overall evaluation upgraded from 3 to 2B
　　with supporting evidence from other relevant data)
　　Pickled vegetables (traditional in Asia) (Vol. 56; 1993)
　　Polybrominated biphenyls [Firemaster BP-6, ] (Vol. 41, Suppl. 7;
　　Toxaphene (Polychlorinated camphenes) [] (Vol. 79; 2001)
　　Toxins derived from Fusarium moniliforme: fumonisin B1 and B2 and fusarin
　　C (Vol. 56; 1993)
　　Welding fumes (Vol. 49; 1990)
　　Exposure circumstances
(Vol. 25, Suppl. 7; 1987)
　　Cobalt metal without tungsten carbide (Vol. 86; 2006)
　　Dry cleaning (occupational exposures in) (Vol. 63; 1995)
　　Printing processes (occupational exposures in) (Vol. 65; 1996)
　　Talc-based body powder (perineal use of) (Vol. 93; in preparation)
　　Textile manufacturing industry (work in) (Vol. 48; 1990)
　　Last updated: 20 December 2006
　　Group 3: Not classifiable as to its carcinogenicity to humans (516)
　　Group 4: Probably not carcinogenic to humans (1)
为本词条添加和相关影像
互动百科的词条（含所附图片）系由网友上传，如果涉嫌侵权，请与客服联系，我们将按照法律之相关规定及时进行处理。未经许可，禁止商业网站等复制、抓取本站内容；合理使用者，请注明来源于。
登录后使用互动百科的服务，将会得到个性化的提示和帮助，还有机会和专业认证智愿者沟通。
您也可以使用以下网站账号登录：
此词条还可添加&
编辑次数：4次
参与编辑人数：4位
最近更新时间： 00:30:08
贡献光荣榜
扫描二维码用手机浏览词条
保存二维码可印刷到宣传品
扫描二维码用手机浏览词条
保存二维码可印刷到宣传品